The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.

Erste Group upgraded Eli Lilly (LLY) to Buy from Hold. Eli Lilly has products that are in high demand as well as “an extensive pipeline of ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiveness overseer NICE.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

At the heart of Eli Lilly's recent success and future prospects are its GLP-1 receptor agonists, Mounjaro (tirzepatide) for diabetes and Zepbound (tirzepatide) for obesity. These drugs have shown ...

Zepbound, developed by Lilly, is an obesity treatment that received approval in November 2023. In South Korea, it is expected to be released under the product name "Mounjaro" in May. Eli Lilly is ...

The new guidance includes revenues of about $3.5 billion for Mounjaro and $1.9 billion for Zepbound and represents 45% growth from the year-ago quarter. Eli Lilly also cut its revenue guidance for ...

Eli Lilly reported a revenue of $13.5 billion, missing the consensus estimate of around $14 billion. The shortfall was attributed to weaker-than-expected sales from its Mounjaro and Zepbound ...

Eli Lilly announced preliminary ... for diabetes drug Mounjaro and obesity drug Zepbound. Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales ...